Anzeige
Meldung des Tages: DiagnosTear Technologies: Zwei Durchstarter für 2026?!
Werbung
Attraktive Knock-Outs auf Sanofi SA
Typ Hebel Bid / Ask WKN
Call
11,4 0,71 € / 0,73 €
CL5WYF
Typ Hebel Bid / Ask WKN
Put
5,3 1,54 € / 1,56 €
SX25M7
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA

Sanofi Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
95,28 $
-1,185 $
-1,23%
80,939 € 24.12.25
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
21,07
Dividende
3,92 €
Dividendenrendite
4,80%
neu: Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter abwärts? Short handeln - Jetzt mit Hebel 7,47: JU1QE3
Werbung

Ad-hocs

17.10.25 - GlobeNewswire
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-​vs-host disease
24.09.25 - GlobeNewswire
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24.09.25 - GlobeNewswire
Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire
23.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-​congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, ...
22.09.25 - GlobeNewswire
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Update on the US regulatory review of tolebrutinib in non-​relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration ...
22.09.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 ...
17.09.25 - GlobeNewswire
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary ...
11.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-​related macular degeneration Designation earned for a one-time intravitreal gene therapy with the ...
10.09.25 - GlobeNewswire
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Tzield approved in China as first disease-​modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
29.08.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-​immune modulation to help address root causes of ...
14.08.25 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related ...
06.08.25 - GlobeNewswire
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc.
31.07.25 - GlobeNewswire
Press release: Online availability of Sanofi’s half-year financial report for 2025
Online availability of Sanofi’s half-year financial report for 2025
31.07.25 - GlobeNewswire
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-​digit sales and solid business EPS growth. 2025 sales guidance is now high single-​digit growth, at upper end of range
30.07.25 - GlobeNewswire
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
25.07.25 - GlobeNewswire
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-​eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that ...
22.07.25 - GlobeNewswire
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a ...
18.07.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025 . Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), ...
17.07.25 - GlobeNewswire
Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025 . Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended ...
16.07.25 - GlobeNewswire
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-​related macular degeneration

Newssuche

Videos

newspaper
26.12.25
Viper Strike Strategie Intro
Strategie-​Paket inklusive Live Online-​Schulung am 4.1. JETZT buchbar ... Mehr »
Anzeige

Aktie im Fokus

DiagnosTear Technologies
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Zwei Durchstarter für 2026?!
Mehr zur Aktie »